Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ELAN

ELAN - Elanco Animal Health Inc Stock Price, Fair Value and News

18.03USD-0.08 (-0.44%)Market Closed

Market Summary

ELAN
USD18.03-0.08
Market Closed
-0.44%

ELAN Alerts

  • 1 major insider buys recently.
  • Big fall in earnings (Y/Y)

ELAN Stock Price

View Fullscreen

ELAN RSI Chart

ELAN Valuation

Market Cap

8.9B

Price/Earnings (Trailing)

-6.84

Price/Sales (Trailing)

2.04

EV/EBITDA

-43.98

Price/Free Cashflow

32.05

ELAN Price/Sales (Trailing)

ELAN Profitability

EBT Margin

-29.58%

Return on Equity

-21.5%

Return on Assets

-9.29%

Free Cashflow Yield

3.12%

ELAN Fundamentals

ELAN Revenue

Revenue (TTM)

4.4B

Rev. Growth (Yr)

-4.14%

Rev. Growth (Qtr)

16.43%

ELAN Earnings

Earnings (TTM)

-1.3B

Earnings Growth (Yr)

-68.93%

Earnings Growth (Qtr)

122.7%

Breaking Down ELAN Revenue

Last 7 days

-1.0%

Last 30 days

5.8%

Last 90 days

14.7%

Trailing 12 Months

76.6%

How does ELAN drawdown profile look like?

ELAN Financial Health

Current Ratio

3.29

Debt/Equity

0.95

Debt/Cashflow

0.07

ELAN Investor Care

Shares Dilution (1Y)

0.33%

Diluted EPS (TTM)

-2.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20244.4B000
20234.4B4.3B4.4B4.4B
20224.7B4.6B4.5B4.4B
20213.9B4.6B4.8B4.8B
20203.0B2.8B2.9B3.3B
20193.1B3.1B3.1B3.1B
20182.9B3.0B3.0B3.1B
20172.9B2.9B2.9B2.9B
20160002.9B
20150002.9B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Elanco Animal Health Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 21, 2024
doyle william f
bought
254,700
16.98
15,000
-
Apr 03, 2024
bettington timothy j
sold (taxes)
-363,484
15.43
-23,557
see remarks
Apr 01, 2024
modi rajeev a.
sold (taxes)
-119,919
15.97
-7,509
see remarks
Mar 08, 2024
doyle william f
bought
244,500
16.3
15,000
-
Mar 08, 2024
harrington michael j
bought
50,493
16.2883
3,100
-
Mar 06, 2024
hoover r david
bought
322,808
16.1404
20,000
-
Mar 05, 2024
young todd s.
gifted
-
-
1,500
see remarks
Mar 05, 2024
young todd s.
gifted
-
-
-37,999
see remarks
Mar 05, 2024
simmons jeffrey n
sold (taxes)
-176,082
15.99
-11,012
president, ceo and director
Mar 05, 2024
young todd s.
gifted
-
-
37,999
see remarks

1–10 of 50

Which funds bought or sold ELAN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
reduced
-1.28
-12,044
81,960
0.01%
Jun 07, 2024
SG Capital Management LLC
new
-
4,211,180
4,211,180
1.38%
May 24, 2024
Cetera Investment Advisers
added
89.22
185,221
358,746
-%
May 20, 2024
Virtu Financial LLC
sold off
-100
-368,000
-
-%
May 16, 2024
Ancora Advisors LLC
added
1.37
16,820,400
173,239,000
3.94%
May 16, 2024
Colony Group, LLC
new
-
186,000
186,000
-%
May 16, 2024
Creekmur Asset Management LLC
unchanged
-
1,158
13,659
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.21
277,297
8,040,660
0.01%
May 16, 2024
Redwood Investment Management, LLC
new
-
1,512,000
1,512,000
0.14%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-78.07
-2,457,580
774,423
-%

1–10 of 40

Are Funds Buying or Selling ELAN?

Are funds buying ELAN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ELAN
No. of Funds

Unveiling Elanco Animal Health Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
dodge & cox
17.0%
83,980,900
SC 13G/A
Feb 13, 2024
vanguard group inc
10.04%
49,468,637
SC 13G/A
Feb 12, 2024
primecap management co/ca/
10.27%
50,600,324
SC 13G/A
Jan 29, 2024
blackrock inc.
5.6%
27,781,483
SC 13G
Nov 08, 2023
primecap management co/ca/
10.28%
50,629,379
SC 13G/A
Sep 11, 2023
vanguard group inc
10.01%
49,307,638
SC 13G/A
Jun 08, 2023
blackrock inc.
4.9%
24,115,385
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
4.0%
18,846,927
SC 13G/A
Feb 14, 2023
dodge & cox
17.9%
84,775,075
SC 13G/A
Feb 09, 2023
primecap management co/ca/
6.96%
32,983,562
SC 13G/A

Recent SEC filings of Elanco Animal Health Inc

View All Filings
Date Filed Form Type Document
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
8-K
Current Report
May 28, 2024
SD
SD
May 23, 2024
4
Insider Trading
May 21, 2024
4
Insider Trading
May 21, 2024
4
Insider Trading
May 08, 2024
10-Q
Quarterly Report
May 08, 2024
8-K
Current Report
May 07, 2024
4
Insider Trading

Peers (Alternatives to Elanco Animal Health Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
350.3B
85.6B
-4.67% -11.11%
9.1
4.09
5.68% 202.39%
327.9B
61.4B
-1.72% 18.35%
142.2
5.34
6.11% -82.30%
160.2B
29.5B
-6.40% 30.72%
42.57
5.42
12.76% -52.47%
156.0B
35.0B
-4.48% -30.74%
134.25
4.45
-26.40% -92.03%
81.1B
27.4B
-2.90% -17.63%
167.32
2.95
1.51% -91.32%
19.3B
16.0B
2.21% 126.25%
-38.95
1.2
7.23% 71.10%
MID-CAP
4.1B
1.7B
1.49% -23.27%
9.54
2.4
54.01% 364.56%
3.7B
4.6B
-11.15% -22.04%
-475.35
0.8
-0.06% 94.55%
2.3B
9.0B
-10.73% -15.05%
-5.09
0.26
10.01% -27.45%
2.0B
676.2M
-4.67% -22.53%
12.79
2.93
30.38% 66.04%
SMALL-CAP
1.3B
743.2M
-18.36% 4.97%
-3.72
1.76
24.65% 80.36%
23.5M
1.3M
-2.39% -46.88%
-3.18
18.07
-98.14% -104.71%
18.0M
89.6M
-7.83% -14.52%
-1.27
0.19
287.27% -129.41%
2.4M
21.5M
-7.89% -89.23%
-0.31
0.11
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Elanco Animal Health Inc News

Latest updates
Defense World14 hours ago
Yahoo Finance07 Jun 202404:00 pm
The Motley Fool08 May 202407:00 am
Investor's Business Daily08 May 202407:00 am

Elanco Animal Health Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In null)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue16.4%1,2051,0351,0681,0571,2579851,0261,1751,2261,1121,1311,2781,2431,140890586658787771782731
Costs and Expenses2.7%1,1931,1622,1651,1361,1491,0741,0701,1891,1511,2371,2611,5151,3221,4601,099663726792784731686
  S&GA Expenses15.4%337292313353327302298343323327342385349374278163182186192201181
  R&D Expenses10.1%87.0079.0086.0081.0081.0080.0078.0082.0081.0092.0094.0094.0089.0011588.0059.0067.0067.0070.0069.0064.00
EBITDA Margin-46.8%-0.07*-0.05*-0.04*0.19*0.20*0.19*0.18*0.16*0.11*0.08*0.05*----------
Interest Expenses-1.5%66.0067.0072.0074.0064.0062.0060.0067.0052.0055.0060.0060.0061.0060.0048.0025.0016.0019.0019.0021.0021.00
Income Taxes-242.9%-20.0014.00-1.0018.005.00-35.0021.00-4.0024.00-15.00-22.00-37.00-13.005.00-74.00-24.00-19.005.00-22.5014.0013.00
Earnings Before Taxes109.4%12.00-127-1,097-79.00108-89.00-44.00-14.0075.00-120-130-243-77.00-318-209-77.00-68.00-4.30-12.5050.0045.00
EBT Margin-9.3%-0.30*-0.27*-0.26*-0.02*-0.01*-0.02*-0.02*-0.04*-0.09*-0.12*-0.16*----------
Net Income122.7%32.00-141-1,096-97.00103-54.00-65.00-10.0051.00-105-108-206-64.00-322-135-53.00-49.00-9.5010.0036.0032.00
Net Income Margin-7.0%-0.30*-0.28*-0.26*-0.03*-0.01*-0.02*-0.03*-0.04*-0.08*-0.10*-0.15*----------
Free Cashflow-Infinity%-22.00-17841.00-165-87.00163286-81.0012464.00132---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-2.4%14,01914,36214,34415,79615,76915,49114,94815,60116,25116,47816,56516,83316,98817,69317,2379,8769,7278,9868,8248,8578,747
  Current Assets18.9%4,0503,4073,5653,6523,5483,2793,1543,3073,1943,2743,1603,4313,3443,4173,2813,1913,1212,3732,3102,3842,278
    Cash Equivalents-2.0%3453523693673183454605073426384535805155066601,3911,206345309385272
  Inventory-5.6%1,6381,7351,6901,6901,5961,5381,3401,3341,3451,3711,3831,4501,4241,5781,5971,0651,0191,0511,0691,0531,036
  Net PPE-7.5%9491,0269921,0071,0009999369619871,0551,0411,0331,2711,3161,243924930955912931930
  Goodwill-12.1%4,4785,0944,9026,0406,0613.005,7165,8986,1166,1726,1916,2396,0166,2256,4353,0443,0042,9902,9462,960-
Liabilities-2.2%7,9638,1398,2108,3768,2898,2028,2038,3488,6398,9708,8838,8538,9819,2178,8933,2243,0663,4393,3363,5913,551
  Current Liabilities-0.7%1,2321,2411,2651,2841,5781,7021,6131,3381,3071,6471,3621,9902,0342,0771,871835708819742778708
  Long Term Debt-0.2%5,7275,7365,8706,0235,6395,4485,5076,0076,0736,0256,2735,5425,5565,5725,5872,0302,0362,3312,3362,3822,437
    LT Debt, Current0%38.0038.0039.0039.0038138839456.0061.0029461.0055560555555426.0026.0025.0025.0027.0029.00
    LT Debt, Non Current-0.2%5,7275,7365,8706,0235,6395,4485,5076,0076,0736,0256,2735,5425,5565,5725,5872,0302,0362,3312,3362,3822,437
Shareholder's Equity-2.7%6,0566,2236,1347,4207,4807,2896,7147,1257,5857,5087,6827,9808,0078,4578,3446,6526,6615,5435,4885,2665,196
  Retained Earnings1.4%-2,256-2,288-2,147-1,051-954-1,057-972-923-901-979-852-748-538-477-154-19.4034.0084.0094.0084.0048.00
  Additional Paid-In Capital0%8,7778,7778,7638,7528,7448,7388,7248,7128,6998,6968,6808,6638,6478,6508,6206,8866,8705,6365,6465,3975,399
Accumulated Depreciation-----7447236966886701,0411,0501,0541,0601,038983942920931909921909
Shares Outstanding0.2%494493493493491474488488488487487487---------
Float----4,900---9,300---16,400---8,600---12,400-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-98.7%2.0015719861.00-14513.00189312-62.0022389.0014922.00-93.00-1121604.0012640.0050.008.00
  Share Based Compensation-26.7%11.0015.0010.009.0012.0015.0013.0017.0014.0018.0017.0016.0015.0016.0012.008.0011.0012.0015.0014.008.00
Cashflow From Investing205.7%37.00-35.00-36.00-43.00-55.00-76.00-37.00-37.00-29.00-74.00-441-25.0010.00-74.00-4,69611.00-20.00-74.50-83.00-46.50-31.00
Cashflow From Financing80.6%-27.00-139-15739.00174-84.00-169-96.00-20044.00231-67.002.00-18.004,0687.00897-6.40-48.8090.00-339
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ELAN Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue$ 1,205$ 1,257
Costs, expenses and other:  
Cost of sales515494
Research and development8781
Marketing, selling and administrative337327
Amortization of intangible assets133134
Asset impairment, restructuring and other special charges4640
Interest expense, net of capitalized interest6664
Other expense, net99
Costs, expenses and other1,1931,149
Income before income taxes12108
Income tax (benefit) expense(20)5
Net income$ 32$ 103
Earnings per share:  
Basic (usd per share)$ 0.06$ 0.21
Diluted (usd per share)$ 0.06$ 0.21
Weighted-average shares outstanding:  
Basic (in shares)493.2491.1
Diluted (in shares)496.0492.8

ELAN Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current Assets  
Cash and cash equivalents$ 345$ 352
Accounts receivable, net988842
Other receivables90168
Inventories1,6381,735
Prepaid expenses and other338310
Assets held for sale6510
Total current assets4,0503,407
Noncurrent Assets  
Goodwill4,4785,094
Other intangibles, net4,1964,494
Other noncurrent assets346341
Property and equipment, net9491,026
Total assets14,01914,362
Current Liabilities  
Accounts payable302270
Sales rebates and discounts318367
Current portion of long-term debt3838
Other current liabilities574566
Total current liabilities1,2321,241
Noncurrent Liabilities  
Long-term debt5,7275,736
Deferred taxes530567
Other noncurrent liabilities474595
Total liabilities7,9638,139
Commitments and Contingencies
Equity  
Common stock, no par value, 5,000,000,000 shares authorized, 494,049,915 and 492,845,216 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively00
Additional paid-in capital8,7778,777
Accumulated deficit(2,256)(2,288)
Accumulated other comprehensive loss(465)(266)
Total equity6,0566,223
Total liabilities and equity$ 14,019$ 14,362
ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. The company was founded in 1954 and is headquartered in Greenfield, Indiana.
 CEO
 WEBSITEelanco.com
 INDUSTRYPharmaceuticals
 EMPLOYEES9000

Elanco Animal Health Inc Frequently Asked Questions


What is the ticker symbol for Elanco Animal Health Inc? What does ELAN stand for in stocks?

ELAN is the stock ticker symbol of Elanco Animal Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Elanco Animal Health Inc (ELAN)?

As of Fri Jun 14 2024, market cap of Elanco Animal Health Inc is 8.91 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ELAN stock?

You can check ELAN's fair value in chart for subscribers.

What is the fair value of ELAN stock?

You can check ELAN's fair value in chart for subscribers. The fair value of Elanco Animal Health Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Elanco Animal Health Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ELAN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Elanco Animal Health Inc a good stock to buy?

The fair value guage provides a quick view whether ELAN is over valued or under valued. Whether Elanco Animal Health Inc is cheap or expensive depends on the assumptions which impact Elanco Animal Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ELAN.

What is Elanco Animal Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, ELAN's PE ratio (Price to Earnings) is -6.84 and Price to Sales (PS) ratio is 2.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ELAN PE ratio will change depending on the future growth rate expectations of investors.